Classification de la néphrite lupique (NL) d'après l'ISN/RPS, vol.50, 2003. ,
, Classe I : NL mésangiale minime
, NL proliférative mésangiale
, NL proliférative focale (< 50% des glomérules atteints) III (A) : lésions actives III (A/C) : lésions actives et chroniques III (C) : lésions chroniques
, NL diffuse (? 50% des glomérules atteints
, IV (A) : lésions actives IV (A/C) : lésions actives et chroniques IV (C) : lésions chroniques
, Classe V : NL extra-membraneuse
, Sclérose avancée (? 90% des glomérules sclérosés sans activité résiduelle) BIBLIOGRAPHIE
Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study, Autoimmun Rev, vol.13, pp.1082-1091, 2014. ,
Systemic lupus erythematosus, Lancet Lond Engl, vol.384, pp.1878-88, 2014. ,
Immunopathogenic mechanisms of systemic autoimmune disease, The Lancet, vol.382, pp.819-850, 2013. ,
,
, Rev Med Interne, vol.35, pp.503-514, 2014.
Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells, J Biol Chem, vol.287, pp.33733-33777, 2012. ,
Autoimmunity and the clearance of dead cells, Cell, vol.140, pp.619-649, 2010. ,
Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, J Exp Med, vol.179, pp.1317-1347, 1994. ,
Taming lupus-a new understanding of pathogenesis is leading to clinical advances, Nat Med, vol.18, pp.871-82, 2012. ,
, N Engl J Med, vol.365, pp.2110-2131, 2011.
Antibodies to DNA, N Engl J Med, vol.338, pp.1359-68, 1998. ,
Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes, PLoS Genet, vol.7, p.1001311, 2011. ,
The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe, Lupus, vol.18, pp.869-74, 2009. ,
What Causes Lupus Flares?, Curr Rheumatol Rep, vol.18, p.14, 2016. ,
Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study, Rheumatol Oxf Engl, vol.43, pp.1039-1083, 2004. ,
Impact of disease activity on health-related quality of life in systemic lupus erythematosus-a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS), BMC Immunol, vol.18, p.17, 2017. ,
Work disability in systemic lupus erythematosus, Arthritis Rheum, vol.61, pp.378-85, 2009. ,
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies, Ann Rheum Dis, vol.69, pp.1269-74, 2010. ,
Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study, PloS One, vol.7, p.45934, 2012. ,
Lupus nephritis biomarkers, Clin Immunol Orlando Fla, 2016. ,
Organ-specific biomarkers in lupus, Autoimmun Rev, vol.16, pp.391-398, 2017. ,
Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis, Autoimmun Rev, vol.12, pp.97-106, 2012. ,
Anti-dsDNA antibodies and resident renal cells-Their putative roles in pathogenesis of renal lesions in lupus nephritis, Clin Immunol Orlando Fla, 2016. ,
Urine miRNA in nephrotic syndrome, Clin Chim Acta Int J Clin Chem, vol.436, pp.308-321, 2014. ,
Diagnosis and management of neuropsychiatric SLE, Nat Rev Rheumatol, vol.10, pp.338-385, 2014. ,
Systemic lupus erythematosus biomarkers: the challenging quest, Rheumatol Oxf Engl, vol.56, pp.32-45, 2017. ,
Annexin A2 autoantibodies in thrombosis and autoimmune diseases, Thromb Res, vol.135, pp.226-256, 2015. ,
An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II, J Biol Chem, vol.269, pp.21191-21198, 1994. ,
Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation, Placenta, vol.17, pp.669-76, 1996. ,
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface, J Biol Chem, vol.279, pp.43411-43419, 2004. ,
Novel organization and properties of annexin 2-membrane complexes, J Biol Chem, vol.279, pp.10872-82, 2004. ,
Specific localization of the annexin II heterotetramer in brain lipid raft fractions and its changes in spatial learning, J Neurochem, vol.90, pp.609-629, 2004. ,
Intracellular annexin A2 regulates NF-?B signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer, Cell Death Dis, vol.6, p.1606, 2015. ,
Annexin A2 could enhance multidrug resistance by regulating NF-?B signaling pathway in pediatric neuroblastoma, J Exp Clin Cancer Res CR, vol.36, p.111, 2017. ,
Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells, J Exp Clin Cancer Res CR, vol.36, p.123, 2017. ,
Annexin A2 system in human biology: cell surface and beyond, Semin Thromb Hemost, vol.39, pp.338-384, 2013. ,
Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome, Blood, vol.107, pp.4375-82, 2006. ,
Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome, J Clin Immunol, vol.28, pp.291-298, 2008. ,
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost JTH, vol.4, pp.295-306, 2006. ,
A novel pathway for human endothelial cell activation by antiphospholipid/anti-?2 glycoprotein I antibodies, Blood, vol.119, pp.884-93, 2012. ,
Update on anti-phospholipid antibodies in SLE: the Hopkins, Lupus Cohort. Lupus, vol.19, pp.419-442, 2010. ,
Toll-like receptors: potential targets for lupus treatment, Acta Pharmacol Sin, vol.36, pp.1395-407, 2015. ,
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus, Clin Exp Immunol, vol.152, pp.482-489, 2008. ,
The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population, Immunobiology, vol.214, pp.392-402, 2009. ,
Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis, Rheumatol Int, vol.31, pp.865-874, 2011. ,
Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis, J Am Soc Nephrol JASN, vol.21, pp.1912-1939, 2010. ,
Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases, Arthritis Res Ther, vol.11, p.93, 2009. ,
Vascular expression of annexin A2 in lupus nephritis, J Clin Pathol, vol.69, pp.533-539, 2016. ,
The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, vol.25, pp.1271-1278, 1982. ,
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, vol.40, p.1725, 1997. ,
The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol JASN, vol.15, pp.241-50, 2004. ,
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE, Arthritis Rheum, vol.35, pp.630-670, 1992. ,
Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer, Cancer Biomark Sect Dis Markers, vol.15, pp.205-216, 2015. ,
Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients, World J Hepatol, vol.9, pp.469-76, 2017. ,
Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study, Pregnancy Hypertens, vol.8, pp.65-74, 2017. ,
Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure, Proteomics, vol.13, pp.2324-2358, 2013. ,
The Annexin A2 System and Vascular Homeostasis, Vascul Pharmacol, vol.54, p.59, 2011. ,
Autoantibodies against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis, Stroke J Cereb Circ, vol.42, p.501, 2011. ,
Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies, Blood, vol.105, pp.1964-1973, 2005. ,
Annexin A2: biology and relevance to the antiphospholipid syndrome, Lupus, vol.17, pp.943-51, 2008. ,
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo, Blood, vol.114, pp.3074-83, 2009. ,
Antiphospholipid syndrome and kidney disease, Kidney Int, vol.91, pp.34-44, 2017. ,
Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus, Lupus, vol.20, pp.721-730, 2011. ,
Annexin A2, autoimmunity, anxiety and depression, J Autoimmun, vol.73, pp.92-101, 2016. ,
Adolescent social isolation affects schizophrenia-like behavior and astrocyte biomarkers in the PFC of adult rats, Behav Brain Res, vol.333, pp.258-66, 2017. ,
Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus, PloS One, vol.10, p.126643, 2015. ,